Business
Cannabics Pharmaceuticals receives "Intention to Grant a European Patent" notice for its System and Method for High Throughput Screening of Cancer Cells patent application
Cannabics Pharmaceuticals receives "Intention to Grant a European Patent" notice for its System and Method for High Throughput Screening of Cancer Cells patent application.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals receives \"Intention to Grant a European Patent\" notice for its System and Method for High Throughput Screening of Cancer Cells patent application\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals receives \"Intention to Grant a European Patent\" notice for its System and Method for High Throughput Screening of Cancer Cells patent application\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, Oct. 27, 2020\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, Oct. 27, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based therapeutic formulations and medicines, announced today that it has been informed by the European Patent Office that the examining division intends to grant the company a European Patent for the Company's  application titled \"A System and Method for High Throughput Screening of Cancer Cells.\"  \n\n \n \n \n \n \n \n\n \nThis patent application relates to the company's CANNABICS™ CDx companion diagnostic drug sensitivity test, whereby a patient's biopsy is screened to match the optimal cannabinoid combination available using the company's high throughput screening of cancer cells proprietary technology. \nOutside the European territory, this patent is also currently being reviewed in other territories including the US and Canada. The decision of the European examiner is significant in that it could also accelerate the review process in other territories who offer a Patent Prosecution Highway such as Canada, India, Mexico and Brazil.  \nGabriel Yariv, Cannabics Pharmaceuticals' President and COO said: \"This patent exemplifies our pioneering vision to bring Cannabinoid-based therapies and treatments to cancer patients worldwide and will strengthen our position as we concentrate on penetrating the European market\". \nDr. Eyal Ballan, Cannabics Pharmaceuticals' CTO, said:\" As pioneers in Cannabinoid-based Cancer diagnostics, we have always believed in the novelty and uniquene...